Replimune Group's melanoma drug Tudriqev received accelerated FDA approval after two prior rejections, based on a 24.20% response rate in trials. Following this, BMO Capital raised its price target for Replimune stock from $16 to $20, indicating strong growth potential. However, the company is under investigation by Pomerantz LLP for possible unlawful business practices related to its clinical data submissions. Investors should watch how this legal scrutiny unfolds alongside the drug's market launch.
Boeing is experiencing ongoing production challenges with its 737 MAX aircraft, causing delays and a recent 3.7% stock drop. Jefferies lowered its price target to $265, still implying a 32% upside from current prices, reflecting cautious optimism. Ba...
Alkermes plc's drug ALKS7290 demonstrated significant improvement in ADHD symptoms in a Phase 1b trial, with patients showing a 14- to 19-point gain on a 54-point scale within two weeks. This outperforms typical placebo effects, which range from 6 to...
BrandPilot AI announced its participation in Marketecture Live 2026 in Chicago, an event that gathers advertising, media, and technology professionals to discuss industry developments. The company aims to engage in discussions about artificial intell...
Meta Platforms shares surged 12% to $747.91 following early success of its new Muse AI assistant, which topped Apple's US App Store with over 730,000 downloads shortly after launch. Wells Fargo raised Meta's price target to $796, citing strong moment...
Ventas reported solid Q2 2026 results with 10% same-store cash NOI growth and 9% normalized FFO/share growth, driven by its dominant senior housing portfolio. Management raised its 2026 FFO/share guidance and acquisition targets, citing a strong bala...
